1. Home
  2. TRDA vs MAX Comparison

TRDA vs MAX Comparison

Compare TRDA & MAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

TRDA

Entrada Therapeutics Inc.

HOLD

Current Price

$6.05

Market Cap

500.4M

Sector

Health Care

ML Signal

HOLD

Logo MediaAlpha Inc.

MAX

MediaAlpha Inc.

HOLD

Current Price

$8.37

Market Cap

516.4M

Sector

Industrials

ML Signal

HOLD

Company Overview

Basic Information
Metric
TRDA
MAX
Founded
2016
2014
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Industrial Machinery/Components
Sector
Health Care
Industrials
Exchange
Nasdaq
Nasdaq
Market Cap
500.4M
516.4M
IPO Year
2021
2020

Fundamental Metrics

Financial Performance
Metric
TRDA
MAX
Price
$6.05
$8.37
Analyst Decision
Strong Buy
Buy
Analyst Count
3
5
Target Price
$21.00
$12.70
AVG Volume (30 Days)
577.1K
584.4K
Earning Date
05-08-2026
04-29-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
25.81
EPS
N/A
0.21
Revenue
$25,421,000.00
$1,113,600,000.00
Revenue This Year
$39.97
$13.42
Revenue Next Year
$50.80
$8.16
P/E Ratio
N/A
$39.40
Revenue Growth
N/A
28.78
52 Week Low
$4.93
$7.09
52 Week High
$16.45
$13.92

Technical Indicators

Market Signals
Indicator
TRDA
MAX
Relative Strength Index (RSI) 29.05 40.18
Support Level $5.58 $7.09
Resistance Level $6.90 $10.10
Average True Range (ATR) 0.97 0.44
MACD -0.55 -0.08
Stochastic Oscillator 3.88 26.90

Price Performance

Historical Comparison
TRDA
MAX

About TRDA Entrada Therapeutics Inc.

Entrada Therapeutics Inc is a clinical-stage biopharmaceutical company. It aims to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The company's Endosomal Escape Vehicle (EEV)-therapeutics are designed to enable the efficient intracellular delivery into a variety of organs and tissues, resulting in an improved therapeutic index and protein-based programs for the potential treatment of neuromuscular and ocular diseases, among others. Its oligonucleotide programs are in development for the potential treatment of people living with Duchenne, which are exon 44, 45, 50, and 51 skipping amenable. It has partnered to develop a clinical-stage program, VX-670, for myotonic dystrophy type 1.

About MAX MediaAlpha Inc.

MediaAlpha Inc provides a platform that enables insurance carriers and distributors to target and acquire customers. The company's technology platform brings insurance carriers and consumers together through a real-time, transparent, and results-driven ecosystem. It serves as a customer acquisition channel in property and casualty insurance, health insurance, and life insurance. The company operates in the United States and generates revenue by earning a fee for each consumer referral sold on its platform.

Share on Social Networks: